|
Combat the COVID-19 |
Highlights |
- A Pilot Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Resistance to therapy and a poor outcome characterize relapsed or refractory acute myeloid leukemia (AML). There is a clear need for additional palliative approaches with acceptable toxicities.
Read More >> - Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia
We conducted a phase 2 trial involving patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Patients were treated with ofatumumab with fresh frozen plasma (FFP) used as a source of complement replacement.
Read More >> - Spontaneous Remission in a Patient With Acute Myeloid Leukemia Leading to Undetectable Minimal Residual Disease
Although rare, spontaneous remission (SR) of acute myeloid leukemia (AML) has been reported in the literature, the underlying mechanisms driving remission remain unknown. However, it is most commonly associated with a preceding severe infection.
Read More >> - Impact of Opioid Use in Hematological Malignancies: Clinical, Immunological and Concomitant Aspects
Opioid agents play a unique role in pain and symptom management for cancer patients. Research shows that opiate use, especially when associated with underlying cancer, has significant effects on hematological parameters.
Read More >> - Outcomes of Reduced Frequency Dosing of Ibrutinib in Chronic Lymphocytic Leukemia Patients Following Complete or Partial Remission: A Pilot Study
Ibrutinib is a Bruton’s tyrosine kinase inhibitor that has shown to be a superior choice in the treatment of chronic lymphocytic leukemia (CLL) and a simple, oral alternative to other chemoimmunotherapies.
Read More >>
Viewpoints |
|
| Featured |
|
| Reduce Mortality and Morbidity in Acute Myeloid Leukemia With Hyperleukocytosis With Early Admission in Intensive Care Unit: A Retrospective Analysis |
Image of the Issue |
![]() Bone Marrow Involvement by Aggressive B Cell Lymphoma Undetected by Aspirate Immunophenotyping |
Current Issue |
|
Vol. 10, No. 1, Feb 2021
Table of Contents
Original Article
A Pilot Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Abstract HTML PDF |
Mary Beth Seegars, Ryan Woods, Leslie R. Ellis, Rupali Roy Bhave, Dianna S. Howard, Megan Manuel, Sarah Dralle, Susan Lyerly, Bayard L. Powell, Timothy S. Pardee | 1-7 |
doi: https://doi.org/10.14740/jh771 |
Use of a Mobile Intermittent Pneumatic Compression Device (Vekroosan) in Mobile Patients With Chronic Venous Disease | Abstract HTML PDF |
Raj Ramakrishna, William Alexander, Lina Baytieh | 8-13 |
doi: https://doi.org/10.14740/jh684 |
Case Report
Bone Marrow Involvement by Aggressive B Cell Lymphoma Undetected by Aspirate Immunophenotyping | Abstract HTML PDF |
Habib Moshref Razavi | 14-17 |
doi: https://doi.org/10.14740/jh766 |
Delayed Hemolytic Transfusion Reaction in a Patient With Sickle Cell Disease and the Role of the Classical Complement Pathway: A Case Report | Abstract HTML PDF |
Pamela S. Hair, Timothy P. Heck, Daniel T. Carr, Katherine D. Watson, Jessica Price, Neel K. Krishna, Kenji M. Cunnion, William C. Owen | 18-21 |
doi: https://doi.org/10.14740/jh553 |
Tamoxifen Therapy for Recurrent Mucosal Bleeding in Hereditary Hemorrhagic Telangiectasia | Abstract HTML PDF |
Stephanie Yung, Julie-Anne Bell, Jim Brooker | 22-24 |
doi: https://doi.org/10.14740/jh794 |
Histologic Transformation in an Untreated Waldenstrom’s Macroglobulinemia After 14 Years: Case Report and Review of the Literature | Abstract HTML PDF |
Elizabeth B. Elimimian, Nadeem Bilani, Maria J. Diacovo, Skirmante Sirvaitis, Chieh Lin Fu | 25-29 |
doi: https://doi.org/10.14740/jh767 |
Spontaneous Tumor Lysis Syndrome: A Rare Presentation in Plasmablastic Lymphoma | Abstract HTML PDF |
Joana Infante, Andre Casado, Antonio Almeida, Antonio Messias | 30-34 |
doi: https://doi.org/10.14740/jh620 |
Letter to the Editor
Similar Outcomes in Early-Failure Steroid-Dependent Compared to Upfront Steroid Refractory Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplant | Abstract HTML PDF |
Dilan A. Patel, Karina A. Mendoza, Heidi Chen, Brian G. Engelhardt, Bipin N. Savani, Stacey A. Goodman, Jeremy Warner, Adetola A. Kassim, Michael Byrne, Wichai Chinratanalab, John P. Greer, Carole Hunt, Madan Jagasia | 35-39 |
doi: https://doi.org/10.14740/jh761 |